Intellia Therapeutics, Inc. (NTLA)

Market Cap	2.14B
Revenue (ttm)	52.60M
Net Income (ttm)	-485.50M
Shares Out	96.48M
EPS (ttm)	-5.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,399,195
Open	22.44
Previous Close	22.47
Day's Range	21.60 - 22.46
52-Week Range	19.37 - 46.50
Beta	1.83
Analysts	Buy
Price Target	66.93 (+202.17%)
Earnings Date	Aug 1, 2024

About NTLA

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 6, 2016
• Employees: 526
• Stock Exchange: NASDAQ
• Ticker Symbol: NTLA

Financial Performance

In 2023, NTLA's revenue was $36.28 million, a decrease of -30.40% compared to the previous year's $52.12 million. Losses were -$481.19 million, 1.48% more than in 2022.

Analyst Forecast

According to 15 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is $66.93, which is an increase of 202.17% from the latest price.

Price Target

$66.93

(202.17% upside)

Analyst Consensus: Buy